Facebook
Twitter
LinkedIn
Forward2020 Medicine Grand Rounds | The Importance of Quality Data Collection of Cutaneous Toxicities in Molecularly Targeted Therapies
Currently, many cutaneous reactions are collected, but are not properly identified in terms of morphology or grade. Because of this, it is often then difficult in future settings to determine if a "rash" is due to the molecularly targeted therapy or to another concurrently administered medication. This necessarily then affects therapeutic decision regarding the treatment of the initial malignant neoplasm. In addition, the grade of the reach is also important to decide if therapy must continue or must be discontinued. The current gap exists because many patients who develop cutaneous toxicities are not necessarily evaluated by a medical professional who is able to correctly classify or grade the adverse effect. Dermatology, as a specialty, needs to be included to help collect and collate this data.
Target Audience
Hematology and oncology physicians and nurses, and all other healthcare professionals interested in the subject matter.
Learning Objectives
- Identify and understand that a number of drugs can cause similar cutaneous toxicities to molecularly targeted therapies.
- Identify and understand that a number of drugs can cause similar cutaneous toxicities to molecularly targeted therapies.
- Outline how the grading according to Common Terminology Criteria for Adverse Events (CTCAE ) guidelines helps to maintain patients on their targeted therapy longer or to discontinue a therapy sooner if necessary to prevent additional morbidity and mortality.
- Identify the new CTCAE cutaneous grading and how proper use of this scale will affect the FDA's understanding of drug toxicity.
Additional Information
| Attachment | Size |
|---|---|
 AB 1195 Bibliography | 250.31 KB |
Conference Room B
Melissa Reyes, MD, MPH, DTMH Medical Officer, United States Public Health Service, US Food and Drug Administration
Dr. Reyes has indicated that she does not have anything to disclose.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this 2020 Medicine Grand Rounds | The Importance of Quality Data Collection of Cutaneous Toxicities in Molecularly Targeted Therapies for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity. - 1.00 Attendance